



Prior Authorization Form

**Arkansas Blue Cross and Blue Shield (Medicare)
Medi-Pak Rx (PDP) and Medi-Pak Advantage (PFFS)
Leukine (Medicare Determination)**

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to CVS|Caremark at 1-888-836-0730.
Please contact CVS|Caremark at 1-800-294-5979 with questions regarding the prior authorization process.
When conditions are met, we will authorize the coverage of Leukine (Medicare Determination).

Drug Name (select from list of drugs shown)

Leukine (sargramostim)

Patient Information

Patient
Name: _____
Patient ID: _____
Patient
Group No.: _____
Patient
DOB: _____

Prescribing Physician

Physician
Name: _____
Physician
Phone: _____
Physician
Fax: _____
Physician
Address: _____
City, State,
Zip: _____

Diagnosis: _____ ICD Code: _____

Please circle the appropriate answer for each applicable question.

- | | | |
|---|---|---|
| 1. Is the physician purchasing and providing the drug "incident to" physician services? | Y | N |
| 2. Will the colony stimulating medication be used concomitantly with chemotherapy or radiation therapy?
[If the answer to this question is yes, then no further questions required.] | Y | N |
| 3. Does the patient have a diagnosis of drug-induced neutropenia?
[If the answer to this question is yes, then may skip to question 20.] | Y | N |
| 4. Is the patient undergoing a peripheral blood progenitor cell (PBPC) collection procedure?
[If the answer to this question is yes, then may skip to question 20.] | Y | N |
| 5. Is the patient undergoing a stem cell transplant?
[If the answer to this question is yes, then may skip to question 20.] | Y | N |
| 6. Is the patient receiving a bone marrow transplant?
[If the answer to this question is yes, then may skip to question 20.] | Y | N |
| 7. Does the patient have a diagnosis of non-myeloid cancer?
[If the answer to this question is no, then may skip to question 13.] | Y | N |
| 8. Is the patient now or will be receiving myelosuppressive anti-cancer drugs? | Y | N |



Arkansas BlueCross BlueShield

An Independent Licensee of the Blue Cross and Blue Shield Association

[If the answer to this question is no, then no further questions required.]

- 9. Is the colony stimulating medication being prescribed for the treatment of acute AFEBRILE (e.g., NOT associated with fever) neutropenia? Y N

[If the answer to this question is yes, then no further questions required.]

- 10. Is the colony stimulating medication being prescribed for the treatment of acute FEBRILE (e.g., fever-associated) neutropenia? Y N

[If the answer to this question is yes, may skip to question 12.]

- 11. Does the patient have a current/prior history of neutropenia (absolute neutrophil count [ANC] less than 1500 cells/mm³) or is the patient at a 20% or greater risk of developing febrile neutropenia with myelosuppressive chemotherapy? Y N

[If the answer to this question is yes, then may skip to question 20. If the answer is no, then no further questions required.]

- 12. Is the patient either at high risk for infection-associated complications or does the patient have prognostic factors that are predictive of poor clinical outcomes? Y N

[If the answer to this question is yes, then may skip to question 20. If the answer to this questions is no, then no further questions required.]

- 13. Does the patient have a diagnosis of acute myeloid leukemia (AML)? Y N

[If the answer to this question is no, then may skip to question 15.]

- 14. Has the patient received induction or consolidation chemotherapy for AML? Y N

[If the answer to this question is yes, then may skip to question 20. If the answer is no, then no further questions required.]

- 15. Does the patient have a diagnosis of severe chronic neutropenia (e.g., congenital, idiopathic, or cyclic)? Y N

[If the answer to this question is yes, then may skip to question 20.]

- 16. Does the patient have a diagnosis of myelodysplastic syndrome? Y N

[If the answer to this question is no, then may skip to question 18.]

- 17. Does the patient have a history of infections? Y N

[If the answer to this question is yes, then may skip to question 20. If the answer is no, then no further questions required.]

- 18. Does the patient have a diagnosis of acquired immune deficiency syndrome (AIDS)? Y N

[If the answer to this question is no, then no further questions required.]

- 19. Is the patient currently receiving antiretroviral therapy for AIDS? Y N

[If the answer to this question is no, then no further questions required.]

- 20. Will complete blood counts (CBCs) with differential and platelet count be done at baseline and regularly throughout therapy? Y N

Comments:

I affirm that the information given on this form is true and accurate as of this date.

Prescriber (Or Authorized) Signature and Date
